Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

13.80 EUR

-1.78 %

5,617 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-1.78 %
-2.82 %
-4.83 %
-5.48 %
-12.66 %
+56.46 %
+224.71 %
+104.95 %
-97.72 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
99.54M EUR
Turnover
82.03K EUR
P/E (adj.) (25e)
78.95
EV/EBIT (adj.) (25e)
71.53
P/B (25e)
19.63
EV/S (25e)
8.43
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.00 EUR
Updated
2026-01-04
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-01-05

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

30/3
2026

General meeting '26

14/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I’ve sketched out the coming years from my perspective and created a Google Sheet that you can copy for your own forecasts. You can open the spreadsheet and select File - Make a copy from the top left corner. In that copy, you can then fill in the fields with the gray background ...
1/6/2026, 10:33 AM
by Kyhnykeisari
23
Thanks @Blindfolded_Monkey for the ideas and help with styling the table. Readability has been improved, and CAGR calculations have been added to the relevant sections. That CAGR really illustrates well how, with fairly moderate sales growth, the bottom line grows at a nice pace....
23 hours ago
by Kyhnykeisari
8
Sinaptica on LinkedIn; Millions of people and families live with Alzheimer’s disease, losing precious memories and time together. The need for new treatment methods has never been greater. At Sinaptica Therapeutics, we are developing a new type of therapy: non-invasive, precise #...
16 hours ago
by Taitoo
6
I don’t know if I’m remembering correctly, but to prevent everyone from just waiting for the NBS6 device, when purchasing an NBS5 device, they were promised a later upgrade to the newer one at a discount. This is what I recall Karvinen saying in an interview, but please correct me...
1/5/2026, 10:20 PM
by ooskari
5
I don’t really see how that would increase realism? In 2025, sales of 13 NBS 5 combination devices and 3 NBS 6 combination devices were announced. I believe that in addition to those, more NBS 6 combination device sales might have been made in Brainlab’s territory that haven’t been...
yesterday
by Kyhnykeisari
4
Yes, I’ve worked through the recurring revenue in those lines 20-30. However, a “brake” of sorts has been added, where only 50% of recurring revenue is calculated for newly sold devices in the first year. The recurring revenue for 2025 is also surely on the low side, as it is largely...
1/6/2026, 11:02 AM
by Kyhnykeisari
4
Big thanks to Kyhnykeisari and colleague. Great table and sensible (not reaching for the moon) figures.
22 hours ago
by Taitoo
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.